Toxoplasmosis in Dogs: Symptoms, Diagnosis, Treatment, and Cyclosporine Risk Guide
This article is reviewed for clinical accuracy. Always consult your veterinarian for diagnosis and treatment.
Key Takeaways
- Toxoplasma gondii is an obligate intracellular protozoan parasite in the phylum Apicomplexa (the same phylum that includes Cryptosporidium, Neospora caninum, and the malaria parasite Plasmodium); it is classified as a coccidian and has a complex life cycle that requires understanding to appreciate the clinical, diagnostic, and zoonotic implications for dog owners; the organism exists in three infectious forms: oocysts produced only in the intestine of the definitive host (cats and other felids), tachyzoites which are the rapidly dividing, tissue-invasive form responsible for acute disease, and bradyzoites which are the slowly dividing form contained within tissue cysts that persist for life in the muscles, brain, and other organs of any infected intermediate host.
- The most critical epidemiological fact about Toxoplasma in dogs is one that is widely misunderstood: DOGS DO NOT SHED TOXOPLASMA OOCYSTS IN THEIR FECES; oocyst shedding occurs only in the intestinal epithelium of cats and other felids, where the sexual cycle of T. gondii is completed; dogs are intermediate hosts where only the asexual cycle occurs; a dog infected with Toxoplasma cannot serve as a source of oocyst environmental contamination and cannot directly transmit Toxoplasma to humans through fecal contact; the environmental oocyst burden that represents the primary transmission risk to humans and other animals originates exclusively from cat fecal contamination of soil, sand, and water, not from dogs; dogs acquire Toxoplasma themselves by ingesting tissue cysts in raw or undercooked meat (most common route), by ingesting sporulated oocysts from cat-contaminated soil or water, or through transplacental transmission from an infected dam.
- Most Toxoplasma infections in dogs are completely subclinical; seroprevalence studies in the United States find that 30 to 40 percent of dogs tested have IgG antibodies to Toxoplasma, indicating prior exposure, while clinical toxoplasmosis is rare in immunocompetent adult dogs; clinical disease occurs primarily in two circumstances: first, in immunocompromised dogs where cell-mediated immunity is suppressed and bradyzoite tissue cysts can reactivate into rapidly dividing tachyzoites that disseminate; second, in very young puppies with immature immune function receiving tachyzoites transplacentally or through nursing; the classic predisposing condition for clinical toxoplasmosis in dogs is concurrent canine distemper virus (CDV) infection, which profoundly suppresses cell-mediated immunity and allows Toxoplasma reactivation; however, iatrogenic immunosuppression with cyclosporine (Atopica, used for atopic dermatitis) is an increasingly recognized and clinically important trigger in veterinary practice, because cyclosporine specifically blocks T-cell activation, which is the primary immune mechanism against Toxoplasma.
- Clinical toxoplasmosis in dogs can affect multiple organ systems depending on which tissues are invaded by tachyzoites during acute disease or reactivation; the most clinically significant manifestations are neurological disease (encephalitis and myelitis causing seizures, cerebellar ataxia, hind limb paresis or paralysis, and cranial nerve deficits), ocular disease (bilateral chorioretinitis is a classic finding in canine toxoplasmosis, along with anterior uveitis and retinal detachment in severe cases), respiratory disease (interstitial pneumonia, which can be severe and rapidly fatal in immunocompromised dogs), and myositis (inflammation of skeletal and cardiac muscle causing weakness and elevated creatine kinase); disseminated toxoplasmosis involving multiple organ systems simultaneously carries a grave prognosis, particularly in immunocompromised dogs.
- Differentiating Toxoplasma gondii infection from Neospora caninum infection is one of the most challenging distinctions in veterinary infectious disease because these two closely related coccidian parasites cause nearly identical clinical presentations, particularly ascending hind limb paralysis with muscle rigidity and polymyositis; the organisms are morphologically indistinguishable on routine histopathology; differentiation requires immunohistochemistry using species-specific antibodies, serological testing (separate IgG titers for Toxoplasma and Neospora at a reference laboratory), or PCR; clinically, Neospora is actually the more common cause of ascending paralysis with pelvic limb hyperextension rigidity in young dogs in most regions of the United States, while Toxoplasma is more likely to be associated with chorioretinitis and pulmonary disease; both organisms respond to the same treatment (clindamycin), so empirical treatment can begin while awaiting serological differentiation.
- Treatment of clinical toxoplasmosis in dogs relies primarily on clindamycin (Antirobe) at 10 to 15 mg/kg orally twice daily for 4 weeks; clindamycin penetrates the blood-brain barrier and the blood-ocular barrier, making it effective for both neurological and ocular manifestations; trimethoprim-sulfadiazine (TMS) at 15 to 30 mg/kg twice daily for 4 weeks is an effective alternative; a critical limitation of all available treatments is that they act against tachyzoites (the actively replicating form during acute infection) but do not eliminate bradyzoite tissue cysts; treatment can resolve clinical signs, halt progression of organ damage, and prevent further tachyzoite dissemination, but it does not clear the infection permanently; a dog that has had toxoplasmosis and then becomes immunocompromised again is at risk for relapse from bradyzoite reactivation; lifelong tissue cyst persistence is why cyclosporine-treated dogs that are seropositive for Toxoplasma are at ongoing risk and may require monitoring or prophylaxis throughout their immunosuppressive treatment course.
The 4-year-old Labrador Retriever had been receiving cyclosporine (Atopica) for 8 months for moderate-to-severe atopic dermatitis when the owner noticed the dog seemed to be having difficulty seeing in dim light; within 2 weeks the dog developed a cloudy appearance to both eyes and began stumbling on stairs; the referring veterinarian noted bilateral chorioretinitis with retinal hemorrhages on fundic examination and a mild cerebellar ataxia on neurological examination; blood work showed a mildly elevated CK and a neutrophilic leukocytosis; Toxoplasma IgG titer came back at 1:1024 and IgM was detectable, consistent with active or recently reactivated infection; Neospora IgG was negative; clindamycin was started immediately at 12.5 mg/kg twice daily, cyclosporine was reduced to the lowest effective dose, and the dog’s visual deficits stabilized at 2 weeks with partial improvement in the ataxia at 4 weeks; the case illustrated the now-recognized risk of Toxoplasma reactivation in dogs on long-term cyclosporine, particularly those in endemic regions who had prior exposure documented by a positive baseline titer.
The Organism and Life Cycle
| Life Stage | Where It Occurs | Infectious Form | Environmental Survival |
|---|---|---|---|
| Oocyst (unsporulated) | Cat intestine; shed in feces immediately after passage; NOT yet infectious | Not infectious when first shed; must sporulate over 1 to 5 days in environment at warm temperature with oxygen | Hours to days (unsporulated) |
| Oocyst (sporulated) | Environment (soil, water, sand) after 1 to 5 days; infectious stage that infects intermediate hosts including dogs and humans | Contains 2 sporocysts each with 4 sporozoites; ingested by intermediate host; excysts in intestine; releases sporozoites that invade enterocytes and then disseminate | Months to years in moist soil; resistant to most disinfectants; killed by boiling water and temperatures above 55 degrees Celsius |
| Tachyzoite | Inside any nucleated cell of any warm-blooded intermediate host (dog, human, rodent, bird, sheep); the acute infection form | Rapidly dividing (tachys = fast); invades virtually all cell types; causes tissue destruction during acute infection; released when infected cells rupture; crosses placenta; killed by stomach acid in healthy hosts | Minutes outside cells; killed by freezing, cooking, and stomach acid |
| Bradyzoite (tissue cyst) | Inside tissue cysts in muscle (skeletal and cardiac), brain, and retina of intermediate hosts; the chronic, persistent form | Slowly dividing (bradys = slow); contained within a cyst wall the host immune system cannot eliminate; persist for the lifetime of the host; reactivate to tachyzoites when cellular immunity is suppressed; transmitted to new hosts when undercooked meat containing cysts is eaten | Within tissue cysts: months to years in muscle and brain; killed by cooking to 67 degrees Celsius internal temperature or by freezing at minus 20 degrees Celsius for 24 or more hours |
How Dogs Get Infected
| Transmission Route | Relative Importance | Prevention |
|---|---|---|
| Ingestion of tissue cysts in raw or undercooked meat | Most common; prey animals (rodents, rabbits, squirrels, birds), raw meat diets, undercooked table scraps; dogs that hunt or scavenge are at highest risk | Cook meat to at least 67 degrees Celsius internal temperature; freeze raw meat at minus 20 degrees Celsius for at least 24 hours before feeding; avoid scavenging of dead wildlife |
| Ingestion of sporulated oocysts from soil or water | Moderate; dogs that dig in or eat soil in areas with cat fecal contamination, dogs that drink from ponds or streams potentially contaminated by feral cat feces | Prevent soil ingestion; avoid water from potentially contaminated natural sources; cover garden beds (cat latrine sites) |
| Transplacental (congenital) transmission | Occurs when pregnant dog has active tachyzoitemia; puppies are born infected or die in utero; associated with primary infection during pregnancy rather than reactivation in most cases | Avoid new Toxoplasma exposure during pregnancy; test breeding females for Toxoplasma titer before breeding if concern exists |
| Transmammary transmission | Minor; tachyzoites can be present in milk during acute tachyzoitemia; neonatal puppies susceptible | Minimize in conjunction with transplacental prevention |
Conditions That Trigger Clinical Disease
Clinical toxoplasmosis in dogs occurs when the immune system cannot contain the organism. The following conditions significantly increase risk:
- Canine distemper virus (CDV) co-infection: historically the most recognized predisposing condition; CDV profoundly depletes lymphocytes and suppresses cell-mediated immunity; clinical toxoplasmosis in dogs was frequently identified post-mortem in CDV-positive dogs before widespread vaccination; CDV and Toxoplasma co-infection is now uncommon in vaccinated populations but occurs in unvaccinated dogs
- Cyclosporine (Atopica, Optimmune): the most clinically significant current cause of iatrogenic toxoplasmosis in dogs; cyclosporine inhibits calcineurin, blocking T-cell activation and interleukin-2 production; T-cell mediated immunity is the primary mechanism for containing Toxoplasma bradyzoite cysts and preventing tachyzoite dissemination; dogs receiving cyclosporine for atopic dermatitis, immune-mediated hemolytic anemia (IMHA), or other conditions are at risk for reactivation of latent infection; risk is higher in dogs with high baseline Toxoplasma IgG titers (indicating a large bradyzoite burden), older dogs, and dogs in regions with high Toxoplasma seroprevalence; some veterinary dermatologists now recommend baseline Toxoplasma serology before initiating cyclosporine in dogs from endemic areas
- Corticosteroids at immunosuppressive doses: prednisone above 2 mg/kg/day or dexamethasone at immunosuppressive doses can predispose to reactivation; the combination of corticosteroids plus cyclosporine (used for some immune-mediated conditions) carries higher risk than either drug alone
- Chemotherapy: cytotoxic agents used for lymphoma (cyclophosphamide, vincristine, doxorubicin) deplete lymphocytes and can trigger Toxoplasma reactivation
- Azathioprine: purine analog immunosuppressant used for IMHA, IBD, and myasthenia gravis; suppresses both T-cell and B-cell function
- Primary immune deficiency: rare inherited immune deficiencies in dogs can predispose to toxoplasmosis at young age without exogenous immunosuppression
- Very young puppies: neonatal immune immaturity; congenitally infected puppies may develop severe disseminated disease in the first weeks of life
Clinical Signs by Organ System
| Organ System | Clinical Signs | Notes |
|---|---|---|
| Neurological (CNS) | Seizures; cerebellar ataxia (wide-based stance, intention tremor); vestibular signs (head tilt, nystagmus, falling); progressive hind limb or forelimb paresis progressing to paralysis; spinal cord signs (myelitis); cranial nerve deficits | Lesion location determines signs; any part of the CNS can be affected; spinal cord lesions can mimic IVDD; brain lesions can mimic neoplasia; MRI shows multifocal enhancing lesions in encephalomyelitis |
| Ocular | Bilateral chorioretinitis (classic finding); anterior uveitis (aqueous flare, corneal edema, miosis); posterior uveitis; retinal detachment; blindness | Bilateral ocular involvement in combination with neurological signs is highly suggestive of Toxoplasma; uveitis alone requires differentiation from other causes (Brucella, Cryptococcus, systemic hypertension, lymphoma); aqueous humor PCR can confirm ocular toxoplasmosis |
| Respiratory | Interstitial pneumonia; progressive respiratory distress; hypoxemia; dry cough; rapid shallow breathing | Can be rapidly fatal in immunocompromised dogs; thoracic radiographs show diffuse interstitial to alveolar pattern; tachyzoites invade Type I and Type II pneumocytes; often accompanies other organ involvement in disseminated disease |
| Muscular | Polymyositis; generalized muscle weakness; stiff, stilted gait; exercise intolerance; muscle pain on palpation; elevated CK and AST; ascending pelvic limb weakness resembling Neospora | Muscle biopsy shows inflammatory infiltrates and tachyzoite or bradyzoite forms; immunohistochemistry needed to differentiate from Neospora; CK elevation supports myopathy component alongside neurological signs |
| Hepatic/GI | Elevated ALT and ALP; hepatomegaly; anorexia; vomiting; diarrhea; jaundice in severe hepatitis | Hepatic involvement more common in neonatal and young puppy disseminated toxoplasmosis; less prominent than neurological and respiratory signs in adult dogs |
| Systemic/Disseminated | Fever; lymphadenopathy; lethargy; weight loss; multiorgan failure in severe cases | Disseminated disease carries grave prognosis; immunocompromised dogs can deteriorate rapidly; aggressive treatment must be initiated immediately without waiting for confirmatory serology |
Toxoplasma vs. Neospora caninum: Key Differences
| Feature | Toxoplasma gondii | Neospora caninum |
|---|---|---|
| Definitive host (oocyst shedding) | Cats (domestic and wild felids) | Dogs (the only known definitive host that sheds oocysts in feces; dogs CAN spread Neospora environmentally) |
| Primary transmission to dogs | Tissue cysts in raw/undercooked meat; sporulated oocysts from cat feces | Transplacental (most important route; dam transmits to pups in utero); tissue cysts in prey; oocysts from dog feces |
| Classic neurological presentation | Multifocal encephalomyelitis; less stereotyped pattern | Ascending pelvic limb paralysis with characteristic rigid hyperextension of the pelvic limbs progressing forward; pelvic limb hyperextension rigidity is the pathognomonic presentation |
| Ocular involvement | Bilateral chorioretinitis is a classic finding; anterior uveitis | Ocular disease less prominent than Toxoplasma; retinal folds and optic neuritis can occur |
| Pulmonary involvement | Interstitial pneumonia common in immunocompromised dogs | Less prominent pulmonary disease |
| Age distribution | Any age; immunocompromised adults most severe | Young puppies (under 6 months) with congenital infection; adults with immunosuppression |
| Diagnosis | Toxoplasma IgG and IgM titer (IFAT, ELISA, MAT); CSF PCR; ocular fluid PCR; muscle biopsy IHC | Neospora caninum IgG titer (IFAT or ELISA); CSF PCR; muscle biopsy IHC (anti-Neospora antibody staining) |
| Treatment | Clindamycin 10 to 15 mg/kg twice daily for 4 weeks | Clindamycin 10 to 15 mg/kg twice daily for 4 weeks (same protocol) |
| Prognosis for neurological disease | Variable; depends on severity and immune status; can improve with treatment | Guarded to poor for dogs with pelvic limb rigidity; early treatment before rigidity establishes gives better outcomes |
Diagnosis
Serology (IgG and IgM Antibody Titers)
The most commonly used diagnostic approach in clinical practice; Toxoplasma IgG titer indicates prior exposure; a single high IgG titer in an asymptomatic dog does not confirm clinical disease because 30 to 40 percent of US dogs have detectable titers from prior subclinical infection; a fourfold or greater rise in IgG titer between samples taken 2 to 4 weeks apart indicates active recent infection; detectable IgM antibody supports active or recent infection because IgM is produced early and wanes within weeks to months, unlike IgG which persists for years; the modified agglutination test (MAT) at a reference laboratory such as the Dubey laboratory at USDA has excellent sensitivity and specificity; IFAT (indirect fluorescent antibody test) and ELISA are also available; it is critical to order BOTH Toxoplasma and Neospora titers simultaneously to allow differentiation, as treatment decisions may differ slightly based on which organism is confirmed even though both respond to clindamycin.
PCR
Polymerase chain reaction on CSF provides a definitive diagnosis of CNS toxoplasmosis; sensitivity is approximately 60 to 80 percent on a single CSF sample (a negative PCR does not rule out CNS disease); PCR on aqueous humor is highly specific for ocular toxoplasmosis; whole blood PCR detects tachyzoitemia during acute disseminated infection; tissue PCR on biopsy or post-mortem samples is definitive; PCR can also differentiate Toxoplasma from Neospora in tissue samples, which is not possible by histopathology alone.
CSF Analysis
CSF in CNS toxoplasmosis typically shows elevated protein (greater than 25 mg/dL) and a lymphocytic or mixed pleocytosis; eosinophilic pleocytosis can occur; these changes are consistent with infectious encephalomyelitis but are not specific for Toxoplasma; CSF should be collected and submitted for both cytology and PCR (Toxoplasma and Neospora) simultaneously to maximize diagnostic yield from a single procedure.
Ophthalmic Examination
Indirect ophthalmoscopy by a veterinary ophthalmologist can characterize the chorioretinal lesions; bilateral active chorioretinitis with retinal hemorrhages and exudates in a dog with neurological signs raises strong suspicion for Toxoplasma; aqueous humor can be collected by paracentesis and submitted for PCR; a single positive aqueous humor PCR is diagnostic for ocular toxoplasmosis.
Note: Fecal Examination Is Not Useful in Dogs
Unlike in cats, fecal examination has no diagnostic value for Toxoplasma in dogs because dogs do not shed oocysts; veterinarians who submit a fecal float to “check for Toxoplasma” in a dog are using the wrong test; serology, PCR, and tissue evaluation are the correct diagnostic approaches in dogs.
Treatment
| Drug | Dose and Duration | Notes |
|---|---|---|
| Clindamycin (Antirobe) | 10 to 15 mg/kg orally twice daily for 4 weeks | Drug of choice; penetrates CNS and eye; active against tachyzoites; also effective for Neospora; available as capsules and oral liquid; GI adverse effects (vomiting, diarrhea) in some dogs; safe in dogs; does not eliminate bradyzoite cysts |
| Trimethoprim-sulfadiazine (TMS) | 15 to 30 mg/kg orally twice daily for 4 weeks | Effective alternative when clindamycin is not tolerated; inhibits Toxoplasma folate synthesis; adverse effects include keratoconjunctivitis sicca (dry eye) with prolonged use; monitor Schirmer tear test; also effective for Neospora at same dose |
| Pyrimethamine + sulfadiazine | Pyrimethamine 1 mg/kg once daily + sulfadiazine 30 mg/kg twice daily for 4 weeks | Used in human medicine for CNS toxoplasmosis; rarely used in dogs due to risk of bone marrow suppression (thrombocytopenia, anemia from antifolate effect); requires folinic acid (leucovorin) supplementation; reserved for cases not responding to clindamycin; requires CBC monitoring every 2 weeks |
| Prednisolone eye drops (topical) | Per ophthalmologist guidance, typically 4 times daily initially | Adjunctive treatment for anterior uveitis to reduce intraocular inflammation; used concurrently with systemic clindamycin; systemic corticosteroids for ocular disease require careful judgment because they suppress the immune response needed to control Toxoplasma |
| Atropine eye drops (topical) | Per ophthalmologist guidance | Adjunctive for uveitis; dilates pupil to prevent synechia (adhesion between iris and lens); reduces ciliary spasm pain |
Cyclosporine Management in Seropositive Dogs
Dogs starting cyclosporine that have a positive baseline Toxoplasma IgG titer are at elevated risk for reactivation; management options discussed with the prescribing veterinarian may include: monitoring for early clinical signs (ocular changes, neurological signs) with a low threshold for investigation; dose reduction to the minimum effective cyclosporine dose; baseline and periodic re-testing of Toxoplasma titers; or in high-risk situations, prophylactic or co-treatment with clindamycin; there is no established universal protocol and clinical judgment is required based on titer level, geographic Toxoplasma burden, and indication for immunosuppression.
Age-Specific Considerations
Puppies (Under 6 Months)
- Congenitally infected puppies are at highest risk of severe disseminated toxoplasmosis because maternal-derived tachyzoites cross the placenta when the dam undergoes primary infection or reactivation during gestation; fetal and neonatal immune systems cannot contain the infection; affected puppies may be stillborn, born weak with respiratory distress, or appear normal at birth but develop rapidly progressive multiorgan disease in the first 1 to 3 weeks of life; the clinical triad of interstitial pneumonia, hepatitis, and CNS signs in a neonatal puppy from a dam without known immunosuppression should raise suspicion for congenital toxoplasmosis
- Puppies born in litters where the dam was on immunosuppressive therapy during pregnancy are at particularly high risk; a dam receiving cyclosporine for atopic dermatitis that had a prior Toxoplasma exposure may experience tachyzoitemia during pregnancy that seeds the fetuses; clindamycin treatment of affected neonatal puppies should be initiated immediately when congenital toxoplasmosis is suspected without waiting for serological confirmation; the prognosis for severely affected neonates is guarded to poor, but puppies with milder neurological signs have recovered with prompt clindamycin treatment
- Young puppies acquiring infection via contaminated soil or prey from an early age are also at risk for clinical disease before their immune systems mature; clinical disease in a puppy under 6 months without a known immunosuppressed dam should prompt testing for Neospora (the more common cause of ascending paralysis in young dogs), Toxoplasma, and canine distemper virus as part of a concurrent infectious disease evaluation; fecal examination is useful in this workup for other parasites but will not detect Toxoplasma oocysts in dogs regardless of age
Adult Dogs (1 to 8 Years)
- Healthy immunocompetent adult dogs virtually never develop clinical toxoplasmosis even with ongoing Toxoplasma exposure from raw meat diets or hunting; a positive Toxoplasma IgG titer in an adult dog without clinical signs requires no treatment and no dietary restrictions; it indicates prior exposure that the dog’s immune system has successfully contained; the titer confirms the presence of bradyzoite tissue cysts but this is clinically insignificant in an immunocompetent dog; only if the dog subsequently becomes immunocompromised do the tissue cysts become a clinical concern
- Adult dogs starting immunosuppressive therapy represent the most important current risk group in clinical practice; cyclosporine for atopic dermatitis is the most commonly implicated drug; signs of reactivation in an adult dog on cyclosporine typically include ocular changes (cloudiness, squinting, behavioral changes suggesting visual loss), changes in gait or coordination, or unexplained muscle weakness; any of these signs in a dog on cyclosporine should prompt immediate ophthalmic examination, Toxoplasma and Neospora serology, and neurological evaluation before the condition progresses; early detection and treatment (clindamycin + cyclosporine dose reduction) provides a much better prognosis than treatment initiated after severe neurological deficits are established
- Adults hunting dogs and dogs on raw meat diets have the highest ongoing exposure to Toxoplasma tissue cysts; while most of these dogs remain subclinical, baseline serology before any planned immunosuppressive therapy is valuable because a high titer indicates a large bradyzoite burden and correspondingly higher reactivation risk; veterinarians managing hunting dogs on cyclosporine or other immunosuppressants should maintain a low threshold for investigating any new neurological or ocular signs
Senior Dogs (9 Years and Older)
- Senior dogs may have accumulated a significant bradyzoite tissue cyst burden from decades of subclinical Toxoplasma exposure, particularly in endemic regions; this is clinically irrelevant unless the dog becomes immunocompromised; age-related immune senescence is a theoretical contributor to Toxoplasma reactivation risk in very old dogs, but overt clinical toxoplasmosis solely from aging without an additional immunosuppressive trigger is uncommon; senior dogs starting cyclosporine or other immunosuppressants for conditions common in older dogs (IMHA, IBD, lymphoma) carry elevated reactivation risk that warrants baseline Toxoplasma serology before initiating treatment
- Senior dogs with neurological disease present a diagnostic challenge because the differential diagnosis list is long (IVDD, neoplasia, Neospora, Toxoplasma, GME, vascular accidents, CDR) and the clinical signs can overlap substantially; Toxoplasma serology and Neospora serology should be included in the diagnostic workup of any senior dog with acute or subacute multifocal neurological disease, particularly if ocular abnormalities are also present; a positive Toxoplasma IgG titer in a senior dog with multifocal neurological signs supports, but does not confirm, Toxoplasma as the causative agent without additional evidence (IgM, fourfold titer rise, or PCR)
- Senior dogs with cancer receiving chemotherapy are at increased risk for Toxoplasma reactivation; lymphoma is the most common canine cancer requiring chemotherapy and the lymphocyte-depleting chemotherapy protocols used for lymphoma (CHOP protocol) significantly suppress cell-mediated immunity; veterinary oncologists managing Toxoplasma-seropositive dogs on chemotherapy should be aware of this risk and include Toxoplasma in the differential for any new neurological signs during chemotherapy
Zoonotic Risk: What Dog Owners Need to Know
The zoonotic risk from a Toxoplasma-infected dog to household members is frequently misunderstood; the following clarifies the actual risk landscape:
- Dogs do not shed oocysts and cannot contaminate the environment with infectious Toxoplasma: the environmental oocyst contamination that represents the primary zoonotic risk to humans comes exclusively from cats; dog feces poses no Toxoplasma transmission risk regardless of the dog’s infection status; routine handling of a dog with toxoplasmosis carries no direct zoonotic risk via fecal-oral contact
- The primary zoonotic risks for humans are: eating undercooked meat containing tissue cysts (pork, lamb, venison, and other game are the most significant sources in the United States); gardening or eating unwashed produce from soil contaminated with cat feces; drinking untreated water contaminated with sporulated oocysts; contact with cat fecal material during litter box cleaning
- Pregnancy and Toxoplasma: primary Toxoplasma infection during pregnancy can cause congenital toxoplasmosis in the fetus, which can result in miscarriage, stillbirth, or neonatal disease (hydrocephalus, chorioretinitis, intracranial calcifications); pregnant women should avoid cat litter box cleaning (or wear gloves and wash hands thoroughly), avoid undercooked meat, and wear gardening gloves; the dog in the household is not a significant source of risk
- Immunocompromised individuals: people with HIV, transplant recipients, and others with significantly impaired cellular immunity are at risk for severe toxoplasmosis from primary infection or reactivation of latent infection; their precautions center on food preparation and cat contact, not dog contact
- Handling a dog with active toxoplasmosis: the tachyzoites present in body fluids of a dog with disseminated toxoplasmosis could theoretically be transmitted by direct mucosal contact with infected tissues, but this is a theoretical risk in clinical circumstances and normal pet-owner interaction poses no practical risk; standard hand washing after handling a sick dog is adequate precaution
Myths and Facts About Toxoplasma in Dogs
My dog tested positive for Toxoplasma so I need to get rid of the dog because it is a risk to my pregnancy.
Dogs do not shed Toxoplasma oocysts and cannot contaminate the environment or infect humans directly. A Toxoplasma-positive dog poses no zoonotic risk to pregnant women via any practical route of transmission. The sources of risk to pregnant women are cats (litter box), undercooked meat, and cat-contaminated soil or produce. The dog in the household is not a source of risk and does not need to be removed. Consult your obstetrician about food safety precautions; your dog is not part of that risk picture.
If I test my dog’s feces for Toxoplasma and it comes back negative, my dog is not infected.
Fecal testing for Toxoplasma is not a valid diagnostic test in dogs because dogs do not shed oocysts regardless of whether they are infected. A negative fecal result provides no information about a dog’s Toxoplasma status. A negative fecal result in a dog with neurological signs absolutely does not rule out toxoplasmosis. The correct tests for Toxoplasma in dogs are serology (IgG and IgM antibody titers), PCR on CSF or ocular fluid, and tissue biopsy with immunohistochemistry.
My dog’s Toxoplasma was successfully treated with clindamycin so the infection is gone and there is no further concern.
Clindamycin treats the active tachyzoite phase of infection and resolves clinical signs, but it does not eliminate bradyzoite tissue cysts from the muscles and brain; the cysts persist for the dog’s lifetime. A treated dog that returns to immunocompetent health is not at further risk for reactivation under normal circumstances. However, if that dog is later placed on immunosuppressive therapy (cyclosporine, chemotherapy, high-dose steroids), the tissue cysts can reactivate and cause a recurrence of clinical toxoplasmosis. Inform any veterinarian prescribing immunosuppressive therapy of the dog’s prior Toxoplasma history.
Red Flags: Signs Requiring Prompt Veterinary Evaluation
- Any new neurological sign in a dog currently on cyclosporine (Atopica), combination immunosuppression, or chemotherapy: ataxia, staggering, apparent visual loss, head tilt, facial drooping, weakness in any limb, new onset seizures, or behavioral changes consistent with disorientation all warrant urgent evaluation; in an immunosuppressed dog, Toxoplasma reactivation progresses rapidly and delaying evaluation significantly worsens prognosis; inform the treating veterinarian of all immunosuppressive medications being given
- Bilateral eye cloudiness, squinting, or apparent visual loss, especially in combination with any neurological sign: bilateral ocular involvement is a hallmark of Toxoplasma and Neospora; unilateral uveitis has a broader differential but bilateral chorioretinitis or anterior uveitis in a dog with gait changes is a neurological emergency requiring same-day evaluation
- Progressive hind limb weakness, stumbling, or rigid pelvic limb posture in a puppy under 6 months: ascending paralysis with rigid hyperextension of the pelvic limbs is the classic presentation of Neospora caninum in young puppies (and can also occur with Toxoplasma); once pelvic limb rigidity establishes, it may not reverse even with treatment; early treatment before rigidity sets in is the single most important factor in prognosis; do not wait to see if a stumbling puppy improves on its own
- Neonatal puppies with respiratory distress, failure to nurse, or rapid deterioration in the first 2 weeks of life when the dam was on immunosuppressive medication during pregnancy: consider congenital toxoplasmosis alongside other neonatal causes; clindamycin treatment can be initiated empirically in neonates that are stable enough to receive oral medication
- Rapid muscle wasting and weakness with a stiff, stilted gait in a dog on immunosuppressive therapy: polymyositis from Toxoplasma or Neospora can progress from subtle gait stiffness to tetraplegia over days in an immunocompromised dog; CK elevation and inability to stand on attempted exercise are indicators of severe myositis requiring immediate evaluation
US Cost Overview for Toxoplasmosis in Dogs
| Service | Typical US Cost |
|---|---|
| Veterinary examination | $60 to $150 |
| Toxoplasma IgG and IgM serology (reference lab) | $80 to $150 |
| Neospora IgG serology (reference lab) | $60 to $120 |
| CSF collection and analysis | $200 to $500 |
| CSF PCR (Toxoplasma + Neospora panel) | $100 to $200 |
| Ophthalmic examination (veterinary ophthalmologist) | $200 to $400 |
| MRI brain and spinal cord | $1,500 to $3,000 |
| Clindamycin (4-week course, 25 kg dog) | $60 to $120 |
| Trimethoprim-sulfadiazine (4-week course, 25 kg dog) | $30 to $70 |
| Total for typical moderate case with serology and treatment | $500 to $1,200 |
| Total for severe neurological case requiring MRI and hospitalization | $3,000 to $8,000 |
Frequently Asked Questions About Toxoplasmosis in Dogs
Can my dog give me Toxoplasma?
No. Dogs do not shed Toxoplasma oocysts in their feces because they are intermediate hosts, not definitive hosts. Only cats shed oocysts. A dog with toxoplasmosis cannot infect you through its feces, saliva, or normal contact. Human Toxoplasma infection comes from eating undercooked meat, gardening in cat-contaminated soil, and contact with cat feces. Your dog is not a source of risk regardless of its infection status.
What are the symptoms of Toxoplasma in dogs?
Most dogs with Toxoplasma have no symptoms. Clinical disease occurs mainly in immunocompromised dogs and causes neurological signs (ataxia, seizures, hind limb weakness), bilateral eye changes (chorioretinitis, uveitis, visual loss), respiratory distress from interstitial pneumonia, and muscle weakness with elevated CK. The combination of bilateral ocular disease and neurological signs in a dog on cyclosporine or other immunosuppressants should prompt immediate Toxoplasma evaluation.
How is Toxoplasma diagnosed in dogs?
Blood serology (Toxoplasma IgG and IgM antibody titers) is the most practical first-line test; a detectable IgM or fourfold IgG rise supports active infection. CSF PCR confirms CNS toxoplasmosis. Aqueous humor PCR confirms ocular toxoplasmosis. Fecal testing is NOT useful because dogs do not shed Toxoplasma oocysts. Always test simultaneously for Neospora caninum since both organisms cause nearly identical disease and require specific serology to differentiate.
How is Toxoplasma treated in dogs?
Clindamycin at 10 to 15 mg/kg orally twice daily for 4 weeks is the treatment of choice; it penetrates the CNS and eye and is effective against tachyzoites. Trimethoprim-sulfadiazine at 15 to 30 mg/kg twice daily is an effective alternative. Treatment resolves clinical signs but does not eliminate bradyzoite tissue cysts, which persist lifelong. Topical prednisolone and atropine eye drops are used concurrently for uveitis. If cyclosporine was the predisposing cause, reducing its dose is part of management.
Is Toxoplasma dangerous for dogs on cyclosporine?
Yes. Cyclosporine blocks T-cell immunity, which is the primary defense against Toxoplasma. Dogs on cyclosporine that have prior Toxoplasma exposure (positive IgG titer) can reactivate their latent bradyzoite tissue cysts into clinically dangerous tachyzoites. Signs of reactivation include new eye cloudiness, neurological signs, or muscle weakness. Baseline Toxoplasma serology is advisable before starting cyclosporine in dogs in endemic areas, and any new neurological or ocular sign in a cyclosporine-treated dog warrants urgent evaluation.
What is the difference between Toxoplasma and Neospora in dogs?
Both are coccidian parasites causing similar neurological and muscular disease. Key differences: Neospora more typically causes ascending pelvic limb paralysis with rigid hyperextension in young puppies, while Toxoplasma more often causes bilateral chorioretinitis and pulmonary disease. Dogs shed Neospora oocysts (dogs are definitive hosts for Neospora) but not Toxoplasma oocysts. Differentiation requires specific serology or immunohistochemistry. Both respond to clindamycin, so treatment need not wait for confirmatory results.
Can a dog recover from Toxoplasma?
Yes, many dogs recover from clinical toxoplasmosis with appropriate clindamycin treatment, particularly when the disease is caught early before severe neurological deficits establish. Prognosis depends on the organ systems affected (ocular and mild neurological disease has better outcomes than severe disseminated disease), the severity of immunosuppression, and how quickly treatment is started. The underlying tissue cyst burden persists lifelong, so dogs that recover must be monitored for reactivation if they subsequently require immunosuppressive therapy.
For more guides on keeping your dog healthy, browse all our Dog Health articles.
Explore Dog Health Articles